Check the unknowns
A short study can miss harm. Keep that gap in view.
US review · small studies
In its September 2026 review, FDA, the US medicine agency, found the studies too small and short to show whether BPC-157 is safe.
Tracking of harm was also unclear in most of the studies.
Headache and gas appeared in healthy volunteers, with no clear difference from the dummy-treatment group.
Read the FDA’s findingsIn its September 2026 review, FDA raised a concern about BPC-157 given by injection or nose spray: the body’s defences may react against it.
The body can make antibodies, proteins that recognise and respond to a substance it sees as foreign. FDA says this immune reaction can cause no noticeable symptoms or can be life-threatening.
Unwanted substances in a batch, or pieces of the peptide stuck together in the medicine, may increase that concern. No study has formally measured these reactions to BPC-157.
This is a possible problem, not a known rate of harm.
Ask the doctor what symptoms to watch for and whom to call. Read the severe allergy signs below.
In September 2026, BPC-157 still has no FDA-reviewed label to explain drug interactions, pregnancy or who must avoid it.
Drug interactions are changes in how medicines act when taken together.
No human pregnancy study appeared in the FDA’s review.
Bring your medicine list and personal questions to the visit. Ask about what matters for your own health history.
MedlinePlus, a US health information service, says a severe allergic reaction can involve breathing difficulty or a swollen face or tongue.
Its advice for severe symptoms is to seek emergency care.
Read MedlinePlus guidance on severe allergyMedWatch is FDA’s system for reporting problems with medical products; patients can send a suspected problem themselves.
A report alone cannot show that a drug caused the problem.
Open the FDA’s MedWatch information